The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours Tiffany FooDavid GoldsteinAmitesh C. Roy Review Article Open access 15 March 2022 Pages: 95 - 110
Estrogen Receptor and the Unfolded Protein Response: Double-Edged Swords in Therapy for Estrogen Receptor-Positive Breast Cancer Ping FanV. Craig Jordan Review Article 15 March 2022 Pages: 111 - 124
Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors Amita PatnaikShirish GadgeelPeter J. O’Dwyer Original Research Article 28 March 2022 Pages: 125 - 138
Correction to: Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors Amita PatnaikShirish GadgeelPeter J. O’Dwyer Correction 05 April 2022 Pages: 139 - 139
Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors Matilda Xinwei LeeAndrea L. A. WongSoo Chin Lee Original Research Article Open access 23 February 2022 Pages: 141 - 151
Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis Suzy Van SandenMolly MurtonAlastair Greystoke Original Research Article Open access 28 February 2022 Pages: 153 - 166
Impact of Dose Intensity on Pathologic Complete Response Rate in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab and Pertuzumab (TCHP) Dat LeCraig VargoMichael Berger Original Research Article 24 March 2022 Pages: 167 - 175
Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers Hiroyuki TakedaKiyomi ImotoYu Sunakawa Original Research Article 02 April 2022 Pages: 177 - 185
Pembrolizumab in Combination with Chemotherapy in Patients with ERBB2-Mutated Non-Small Cell Lung Cancer Fawzi Abu RousRadhika GuttaShirish Gadgeel Short Communication 21 March 2022 Pages: 187 - 192
Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma Anthony Markham Adis Drug Evaluation 17 February 2022 Pages: 193 - 201
